MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Wang, Lu Kai ^a   Hsiao, Tzu Hung ^b   Hong, Tse Ming ^c   Chen, Hsuan Yu ^d   Kao, Shih Han ^b   Wang, Wen Lung ^e   Yu, Sung Liang ^b   Lin, Ching Wen ^e   Yang, Pan Chyr ^a,b,e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MEMBRANE RECEPTOR; MICRORNA; MICRORNA 133A; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; MIRN133 MICRORNA, HUMAN; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHUS MUCOSA; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DOWN REGULATION; GENE SILENCING; GENETICS; LUNG NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ONCOGENE PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84901228446     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096765     Document Type: Article

References (37)

1. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355: 479-485. (Pubitemid 30085163)
2. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382: 709-719.
3. Tufman A, Tian F, Huber RM (2013) Can MicroRNAs Improve the Management of Lung Cancer Patients? A Clinician's Perspective. Theranostics 3: 953-963.
4. Cooper WA, Lam DC, O'Toole SA, Minna JD (2013) Molecular biology of lung cancer. J Thorac Dis 5: S479-S490.
5. Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382: 720-731.
6. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, et al. (2014) A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). J Thorac Oncol 9: 154-162.
7. Mitsudomi T, Suda K, Yatabe Y (2013) Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol 10: 235-244.
8. Scagliotti GV, Novello S (2012) The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 38: 292-302.
9. Santibanez JF, Quintanilla M, Bernabeu C (2011) TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 121: 233-251.
10. Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597-610.
11. Ling H, Fabbri M, Calin GA (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865.
12. Ebert MS, Sharp PA (2012) Roles for microRNAs in conferring robustness to biological processes. Cell 149: 515-524.
13. Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, et al. (2013) MicroRNA- 135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun 4: 1877.
14. Peng Y, Dai Y, Hitchcock C, Yang X, Kassis ES, et al. (2013) Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci U S A 110: 15043-15048.
15. Koutsoulidou A, Mastroyiannopoulos NP, Furling D, Uney JB, Phylactou LA (2011) Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle. BMC Dev Biol 11: 34.
16. Uchida Y, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, et al. (2013) MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol 31: 115-123.
17. Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Fujimura L, et al. (2011) Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol 38: 209-217.
18. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, et al. (2012) Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106: 405-413.
19. Moriya Y, Nohata N, Kinoshita T, Mutallip M, Okamoto T, et al. (2012) Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 57: 38-45.
20. Tai CJ, Wu AT, Chiou JF, Jan HJ, Wei HJ, et al. (2010) The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging. BMC Cancer 10: 95.
21. Chen Y, Zhao YH, Di YP, Wu R (2001) Characterization of human mucin 5B gene expression in airway epithelium and the genomic clone of the aminoterminal and 5′-flanking region. Am J Respir Cell Mol Biol 25: 542-553. (Pubitemid 33087104)
22. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, et al. (1997) Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17: 353-360. (Pubitemid 127500840)
23. Hsu YC, Yuan S, Chen HY, Yu SL, Liu CH, et al. (2009) A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer. Clin Cancer Res 15: 7309-7315.
24. Wu W, Bi C, Credille KM, Manro JR, Peek VL, et al. (2013) Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Clin Cancer Res 19: 5699-5710.
25. Cheung M, Testa JR (2013) Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 13: 234-244.
26. Meng XN, Jin Y, Yu Y, Bai J, Liu GY, et al. (2009) Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer 101: 327-334.
27. Choi EJ, Ryu YK, Kim SY, Wu HG, Kim JS, et al. (2010) Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol Cancer Res 8: 1027-1036.
28. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, et al. (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57.
29. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, et al. (2010) MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70: 8288-8298.
30. Kaklamani VG, Pasche B (2004) Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 4: 649-661. (Pubitemid 39161996)
31. Singh I, Amin H, Rah B, Goswami A (2013) Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer. Front Biosci (Schol Ed) 5: 231-246.
32. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, et al. (2010) miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814.
33. Tao J, Wu D, Xu B, Qian W, Li P, et al. (2012) microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep 27: 1967-1975.
34. Cui W, Zhang S, Shan C, Zhou L, Zhou Z (2013) microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. FEBS J 280: 3962-3974.
35. Chong CR, Janne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19: 1389-1400.
36. Seccareccia E, Brodt P (2012) The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Horm IGF Res 22: 193-199.
37. Wen D, Li S, Ji F, Cao H, Jiang W, et al. (2013) miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer. Tumour Biol 34: 793-803.